HT4 Proceso De Incorporación De Fármacos A La Lista Positiva De Medicamentos (Lpm) Para Los Prestadores Integrales De Salud: Experiencia En El Ministerio De Salud Pública (Msp) De Uruguay  by Croci, A et al.
A810  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 8 0 5 – A 8 8 1  
study shows that mere recommendation by CONITEC doesn’t guarantee access 
for the population in the timeframe established. Reasons should be investigated.
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Objectives: Describir el proceso para la de incorporación de fármacos al LPM en 
el marco del Sistema Nacional Integrado de Salud Uruguayo MethOds: El pro-
ceso comienza con la presentación de un formulario de solicitud al MSP al que se 
adjunta evidencia de alta calidad de su eficacia y seguridad comparado con las 
alternativas terapéuticas. Esta evidencia es analizada y complementada con una 
nueva búsqueda bibliográfica sistemática realizada por el evaluador. Se resumen 
los resultados de eficacia y seguridad obtenidos de estudios aleatorizados presen-
tados y cuando hay más de uno y es metodológicamente adecuado se realizan meta 
análisis. Si no hay estudios de comparación cabeza a cabeza se realizan en ocasiones 
comparaciones indirectas. Los informes de eficacia y seguridad son posteriormente 
evaluados por un experto clínico quienes aportan su punto de vista en cuanto a la 
pertinencia de la inclusión. Finalmente en los casos candidatos a ingresar se realiza 
un análisis económico (impacto presupuestal o estudios de costo utilidad según 
el precio del tratamiento anual sea menor o supere un PBI per cápita). Results: 
En 2011 solicitaron ingreso al FTM 123 fármacos, en 2012 fueron 37 fármacos, en 
2013 fueron 30 fármacos y en 2014 fueron 51 lo que totaliza 241 solicitudes. De 
estas, todos fueron completamente revisados, 54 fueron rechazados por insuficiente 
evidencia presentada, 163 tienen informes de eficacia y seguridad completos y 24 
están siendo evaluados en este sentido. De los 163 evaluados, 61 tienen pendientes 
evaluaciones clínica o económicas. cOnclusiOns: El desarrollo de un sistema de 
evaluación de tecnologías para informar a los decisores sobre la incorporación de 
nuevos fármacos a las listas positivas de medicamentos de los sistemas únicos de 
salud, requiere de tiempo y pericia técnica, pero es posible en entornos de recursos 
limitados y representa un avance con respecto a modalidades anteriores.
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Objectives: Clinical trials (CT) represent an important alternative treatment 
for oncologic patients. Also, CTs represent an important step to development of 
improved therapeutic strategies. On the other hand, little is known on Brazilian 
patient’s perception regarding CT. Therefore, the aim of this survey was to describe 
the overall perception of clinical research in Brazil. MethOds: From April 2012 
until October 2014, 254 respondents answered an internet-based survey related 
to knowledge related clinical research from Oncoguia Institute, an independent 
nonprofit cancer advocacy institution. Results: Overall, about 85% of respondents 
would participate on oncology trial. Of all respondents, 99.9% believe that clinical 
research can contribute positively to advance of cancer treatment by increasing 
the scientific knowledge, improvement of treatment, finding a cure, to have a new 
treatment option, or improved quality of life. Among the respondents, 96% affirmed 
that have already had some information on clinical research, being internet the 
most used form of communication (69%), followed by physicians´ orientation (8%), 
magazines and newspaper (8%) and hospital hand-out material (7%). In addition, 
only 18 respondents reported previously participation on CT (6.9%), and about 10% 
answered that have someone known that participated in a clinical trial (e.g. friend, 
family or other). cOnclusiOns: This survey demonstrates that respondents associ-
ate clinical research as an option in cancer treatment. However, only a small number 
of respondents have participated previously of a CT, besides that, internet was the 
main tool to learn about CTs. The data indicate that lack of available information, 
including low participation of physician on instructing their patients, are the current 
major barriers on CT in Brazil. Improvement of physician and patient awareness are 
potential solutions. Thus, strategies are needed to improve communication between 
patient and physician.
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Objectives: To derive a value set from Uruguayan general population using the 
new five level (5L) EQ-5D instrument and report population norms. MethOds: 
We randomly assigned general population individuals to value 10 health states 
using composite Time Trade Off and 7 pairs of health states through Discrete 
Choice Experiments. Additionally, respondent provided socidemographic infor-
mation and rated their current health state. The sample was stratified using with 
quotas by location, gender, age and socioeconomic status in order to represent 
the Uruguayan population structure. Trained interviewers conducted face to face 
interviews using EuroQol valuation technology (EQVT) to administer the protocol, 
as well as to collect and store the data. Primary analysis used OLS and maximum 
likelihood robust regression models with or without interactions Results: We 
included 794 respondents between 20 and 83 years. Their characteristics were 
in 2010, being the fourth main cause of death. WHO estimated the prevalence of DM 
in Brazil is 10.2%, about 20 million people. Objectives: To measure the DM social 
cost based in earnings losses of Brazilian workers due to disease in 2008 using 
data from National Survey of Households (PNAD/IBGE). MethOds: A Binary Probit 
model to measure the participation in work force and a two-stage Heckman model 
to measure worked hours and productivity. Each model is estimated separately 
for both gender individuals, with and without disease, according three distinct 
definitions for DM: Restrict, Broad and Comorbidities. To capture the counterfactual 
effect, the model was calculated for ill and healthy individuals. The difference of 
both values exhibited the losses, which were aggregate to the whole population and 
the total cost was estimated. Results: According each criterion, respectively, DM 
reduced the participation in the labor market in 0,97%; 4,60% and 7,06% for men 
and 0,14%; 4,79% and 6,44% for women, while reduced, respectively 1,51%; 6,40% 
and 9,15% in productivity and 6,44%; 15,23% and 17,58% in worked hours just for 
women. There was no impact of DM on productivity and in worked hours for men. 
The DM total cost was R$ 8,064 billion, or US$ 3,451 billion converted by current 
exchange rate. The losses reached 0,73% of total earnings and 0,27% of Brazilian 
GDP in 2008. cOnclusiOns: DM generates significant losses in income of Brazilian 
workers, especially in relation to their participation in the labor market, since affects 
both of gender. The results indicate that public policies should be directed to dis-
ease diagnosis and prevention, since the development of comorbidities amplifies 
the effect of losses.
HeaLTH TecHnoLogy assessmenT sTuDIes
HT1
raPID Increase oF HeaLTH LITIgaTIon as a means oF markeT access For 
InnovaTIve meDIcInes In coLombIa anD THe PoTenTIaL roLe oF HeaLTH 
TecHnoLogy assessmenT
Leon Kershaw A, Izmirlieva M
IHS, London, UK
Objectives: Reimbursement of high-cost medicines excluded from the Colombian 
mandatory healthcare plan (POS) through legal mechanisms known as ‘tutela’ and 
the Scientific Technical Committees (CTC) have significantly increased in the last 
four years. As the new healthcare statutory law (1751-2015) puts pressure on the 
healthcare budget, it is likely that these will increase further. This research analy-
ses the “judicialisation” of the right to health in Colombia and the feasibility of a 
mandatory health technology assessment (HTA) evaluation as a policy to reduce 
reimbursement of non-POS medicines by litigation. MethOds: Secondary research 
of the main tutela decisions of the Colombian courts and CTC decisions related to 
non-POS medicines between 2011 and 2014 were conducted. A 2014 Ombudsman’s 
Office report of detailed medicine-tutelas was also analysed, and cross-referenced 
with statistics from the Colombian Ministry of Health and the General Prosecutor. 
A lack of official data for 2014 is addressed using case-by-case tutelas, literature 
review and stakeholder interviews. Results: Tutela and CTC decisions are pre-
dominantly in favour of protecting the fundamental right to health (80% of all deci-
sions between 2011 and 2014), giving access to non-POS medicines irrespective of 
cost-effectiveness. According to the Ombudsman’s Office, of the 115,147 tutelas 
presented in 2013, 34,099 (18.8%) were requests for medicines of which over half 
(22,685) were for access to non-POS medicine. The Colombian Fund of Solidarity and 
Guarantees paid health-promoting entities (EPS) over COP2 billion in 2012 and over 
2.5billion in 2013 for the reimbursement of non-POS medicines following tutela and 
CTC decisions. cOnclusiOns: Decisions over access to many high-cost medicines 
in Colombia are taken in courts based on infringement of fundamental rights rather 
than on cost and clinical-effectiveness assessments. This provides an important 
avenue to access new medicines, but also side-steps the formal reimbursement pro-
cess. A more systematic, binding HTA system would likely reduce health litigation.
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Objectives: Brazilian Federal Law 12.401/2011 created the National Committee 
for Health Technology Incorporation (CONITEC) and defined criteria and deadlines 
for health technology (HT) incorporation in public health system (SUS). CONITEC 
advises the Brazilian Ministry of Health about HT incorporation or disinvestment 
in SUS and clinical guidelines development. After CONITEC appraises and recom-
mends a technology, it should be available for the population in 180 days. The 
objective of this analysis was to evaluate the time between a technology was rec-
ommended by CONITEC and actually became available. MethOds: We reviewed 
all CONITEC’s reports since 2012, and selected those regarding drugs. Reports 
were classified in not recommended and recommended, and publication date was 
retrieved for those recommended. Simultaneously, we evaluated the date a drug 
recommended by CONITEC was received by the Centro de Medicamentos Básicos 
do Paraná (CEMEPAR), which is responsible for buying and distributing medica-
tions in Paraná. The time between report publication and drug availability was then 
assessed. Results: CONITEC published 125 reports since 2012, 93 on drugs and 42 
classified as recommended. These 42 represented 62 drugs with different pharma-
cologic concentrations. From these, it was the Paraná state’s liability to distribute 
45, which were then selected for the analysis. The majority of cases (64.4%) were in 
non-conformity with established deadlines: 55.5% were unavailable at CEMEPAR 
before 180 days, and 8.9% were never bought until the day of this analysis (February 
06th, 2015). The longest time between drug recommendation and its availability at 
CEMEPAR was 2 years and 73 days (salmeterol 50mcg) and the minimum was 13 
days (adalimumab 40mg). Average time for a drug to be available for distribution 
was 315.3 days (135.3 days beyond the established deadline). cOnclusiOns: This 
